The BalancedInvestor Club

STRO Market Analysis

Overview

Fundamentals

P/E ratio—Forward 8.96
EPS (TTM)$-22.490.0% YoY
Profit margin-186.5%HEALTHCARE
Market cap$589.7MSmall cap

Wall Street coverage

$35.73median target· current $38.90 (-8.1%)12 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
8.96
PEG ratio
—
P/B
2.11
P/S (TTM)
5.75
EV/EBITDA
41.71

Profitability & growth

ROE (TTM)
-1810.0%
Operating margin
-289.0%
Revenue growth YoY
-21.4%
Dividend yield
—
Beta
1.31
Last earnings
Mar 12, 2026 · Estimate $-0.43 · Reported $-5.45
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.

Classification

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$589.7M
Shares outstanding$16.6M
52W high$39.10
52W low$6.74

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer